D. Colburn

发表

Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

E. Estey, A. Rashid, H. Kantarjian, 2001, Cancer.

Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential

P. LoRusso, S. Piha-Paul, A. Colevas, 2012, Cancer Chemotherapy and Pharmacology.

Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia

F. Giles, Deborah A. Thomas, D. Colburn, 2003, Investigational New Drugs.

In Vitro Evaluation of Cytochrome P450-mediated Drug Interactions between Cytarabine, Idarubicin, Itraconazole and Caspofungin

F. Giles, Judith A. Smith, D. Colburn, 2004, Hematology.

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

H. Kantarjian, J. Cortes, S. Verstovsek, 2003, Cancer Chemotherapy and Pharmacology.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

A. Krämer, J. Cortes, K. Yee, 2018, British journal of haematology.

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

Priya Chandra, C. Hop, R. Graham, 2016, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors

J. Berlin, A. Jimeno, P. LoRusso, 2011, Clinical Cancer Research.

Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies

T. Hartung, D. Roethlisberger, Z. Pápai, 2020, Clinical pharmacology in drug development.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

M. Maitland, P. LoRusso, G. Abou-Alfa, 2017, Cancer Chemotherapy and Pharmacology.

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis

A. Surinach, N. Sadetsky, D. Colburn, 2020, Cancer medicine.

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

M. Borin, I. Chang, C. Hop, 2012, British journal of clinical pharmacology.

A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

P. Rutkowski, M. Błasińska-Morawiec, R. Herbst, 2019, The British journal of dermatology.

Abstract B188: Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors.

P. LoRusso, S. Piha-Paul, A. Colevas, 2011 .

Skin Infiltration with Chronic Lymphocytic Leukemia is Consistent with a Good Prognosis

F. Giles, D. Colburn, M. Welch, 2002, Hematology.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

J. Hainsworth, V. Miller, F. Kabbinavar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Connie Y. C. Ma, M. Kockx, C. Green, 2019, Blood.

1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)

Melissa L. Johnson, O. Gardner, H. Gilbert, 2020, Annals of Oncology.

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy

L. Demidov, Jeeyun Lee, T. Kim, 2018, Journal of clinical pharmacology.

Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects.

J. Rinehart, D. Young, D. Colburn, 1987, Journal of biological response modifiers.